Allogene Therapeutics
Danielle Dishmon has a diverse work experience in the pharmaceutical industry. Danielle is currently working as the Executive Director of Global Medical Affairs at Allogene Therapeutics since April 2023. Prior to that, they were the Senior Director of Scientific Communications at Instil Bio from September 2021 to April 2023. From September 2020 to September 2021, they held the same role at Turning Point Therapeutics.
Before these positions, Danielle Dishmon worked at Kite Pharma as the Director of Global Medical Affairs from July 2019 to September 2020. Prior to that, they were the Associate Director of Medical Communications at the same company from July 2017 to July 2019. Danielle also gained experience at Genentech as a Managed Care Medical Communication Scientist from February 2015 to July 2017.
Danielle Dishmon began their career in the pharmaceutical industry at Janssen, Pharmaceutical Companies of Johnson and Johnson, where they served as a Senior Medical Science Liaison from September 2013 to February 2015. Previously, they worked at Eli Lilly and Company as a Medical Liaison from June 2011 to August 2013 and as a Visiting Scientist in Clinical Pharmacology from June 2010 to June 2011.
Prior to their career in the pharmaceutical industry, Danielle Dishmon gained experience as a Pharmacy Intern at Target from 2007 to 2010.
Danielle Dishmon completed their Bachelor of Science degree in Biology at Arizona State University, from 2001 to 2005. Afterward, from 2006 to 2010, they pursued further education at Western University of Health Sciences, where they obtained their PharmD degree. The field of study for their PharmD degree is not specified.
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.